4.365USD+0.34%Mkt Cap: 483.73M USDP/E: —Last update: 2026-06-01
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targ…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap483.73M USD
Enterprise Value305.95M USD
Revenue (TTM)34.86M USD
Gross Profit25.88M USD
Net Income (TTM)-104.99M USD
Revenue/Share0.3600 USD
Last Price4.365 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.78
PEG—
EV/EBITDA-3.02
EV/Revenue8.78
P/S13.86
P/B1.94
EPS (TTM)-1.10
EPS (Forward)-1.16
52W Range
1.21093% of range4.598
52W High4.598 USD
52W Low1.210 USD
Profitability
Gross Margin74.25%
Oper. Margin-451.64%
EBITDA Margin-290.30%
Profit Margin-292.08%
ROE-40.92%
ROA-29.24%
Growth
Revenue Growth-15.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.69M USD
CapEx (TTM)607.00K USD
FCF Margin-144.96%
FCF Yield-10.45%
Net Debt-177.22M USD
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.23
Current Ratio9.01
Quick Ratio8.76
Book Value/Sh2.252 USD
Cash/Share2.131 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.57 USD
Target Range6.000 USD – 30.00 USD
# Analysts7
Ownership
Shares Out.110.57M
Float79.64M
Insiders1.13%
Institutions85.16%
Short Interest
Short Ratio7.6d
Short % Float19.35%
Short % Out.19.22%
Shares Short21.25M
Short (prev mo.)21.04M
Technical
SMA 502.959 (+47.5%)
SMA 2002.551 (+71.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)2.71M
Avg Vol (10d)2.01M
Technical Indicators
RSI (14)73.8
MACD0.2549
MACD Signal0.1825
MACD Hist.+0.0724
BB Upper4.095 USD
BB Middle3.349 USD
BB Lower2.603 USD
BB Width44.55%
ATR (14)0.3286 USD
Vol Ratio (20d)1.73x